Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year High – Time to Buy?

Posted by Brenda Bartman on Jul 23rd, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $95.68 and last traded at $95.5090, with a volume of 92458 shares traded. The stock had previously closed at $91.57.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CORT. Canaccord Genuity Group raised their price objective on Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. UBS Group set a $135.00 target price on shares of Corcept Therapeutics in a report on Thursday, May 28th. HC Wainwright raised their target price on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Wolfe Research raised shares of Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a report on Thursday, March 26th. Finally, Truist Financial upgraded shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, Corcept Therapeutics has an average rating of “Moderate Buy” and an average price target of $88.83.

Check Out Our Latest Stock Analysis on CORT

Corcept Therapeutics Stock Down 5.0%

The business has a 50 day moving average price of $78.85 and a two-hundred day moving average price of $53.77. The stock has a market cap of $9.76 billion, a P/E ratio of 259.66 and a beta of 0.47.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The business had revenue of $164.90 million for the quarter, compared to the consensus estimate of $185.83 million. During the same period last year, the business posted $0.17 EPS. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 0.53 earnings per share for the current year.

Insider Activity

In other news, Director James N. Wilson sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $83.20, for a total value of $832,000.00. Following the transaction, the director owned 1,094,543 shares of the company’s stock, valued at approximately $91,065,977.60. The trade was a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sean Maduck sold 25,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $88.35, for a total transaction of $2,208,750.00. Following the completion of the transaction, the insider directly owned 9,755 shares in the company, valued at $861,854.25. This trade represents a 71.93% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 300,000 shares of company stock valued at $22,088,050. Company insiders own 20.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CORT. Parallel Advisors LLC increased its holdings in shares of Corcept Therapeutics by 2.5% in the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock worth $160,329,000 after purchasing an additional 96,763 shares during the last quarter. State Street Corp boosted its stake in Corcept Therapeutics by 0.5% during the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after buying an additional 15,656 shares during the last quarter. Geode Capital Management LLC boosted its stake in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares during the last quarter. First Trust Advisors LP grew its holdings in Corcept Therapeutics by 213.5% during the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares in the last quarter. Finally, Morgan Stanley grew its holdings in Corcept Therapeutics by 34.1% during the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after buying an additional 405,081 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.